{"publication_id":"ab40c73a-dca5-4102-8b82-441a90f13b37","content_hash":"sha256:1e155b2aed565577b474820268e90efb7cfca29d604687b44497e9f8d6d39543","nodes":[{"id":"ab40c73a-dca5-4102-8b82-441a90f13b37","type":"publication","title":"Metformin has a live counter-signal"},{"id":"claim_1","type":"claim","text":"Interpretation note:** This is a hypothesis-generating alpha memo, not confirmatory evidence; subgroup or context-derived claims require independent replication."},{"id":"claim_2","type":"claim","text":"`fact_id=166319` (`A_core`) — Metformin (0.1%) combined with rapamycin (14 ppm) robustly extended lifespan, suggestive of an added benefit. doi=10.1111/acel.12496"},{"id":"source_1","type":"source","study":"Use of metformin and survival of patients with high‐grade glioma","year":2018,"doi":"10.1002/ijc.31783","url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_2","type":"source","study":"Association Between Preadmission Metformin Use and Outcomes in Intensive Care Unit Patients With Sepsis and Type 2 Diabetes: A Cohort Study","year":2021,"doi":"10.3389/fmed.2021.640785","url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_3","type":"source","study":"Metformin in Patients With COVID-19: A Systematic Review and Meta-Analysis","year":2021,"doi":"10.3389/fmed.2021.704666","url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_4","type":"source","study":"Metformin in the prevention of hepatocellular carcinoma in diabetic patients: A systematic review","year":2019,"doi":"10.1016/j.aohep.2019.10.005","url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_5","type":"source","study":"Longer lifespan in male mice treated with a weakly estrogenic agonist, an antioxidant, an α‐glucosidase inhibitor or a Nrf2‐inducer","year":2016,"doi":"10.1111/acel.12496","url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"}],"edges":[{"from":"ab40c73a-dca5-4102-8b82-441a90f13b37","to":"claim_1","type":"contains_claim"},{"from":"ab40c73a-dca5-4102-8b82-441a90f13b37","to":"claim_2","type":"contains_claim"}],"screening":{"identified":5,"screened":5,"excluded":0,"included":5,"included_or_retained":5,"flow":["identified","screened","excluded_with_reasons","included"],"wording":"5 candidate receipts retained after source retrieval, deduplication, and topic filtering. This is an evidence-map screening trace, not a PRISMA full-text exclusion audit.","exclusion_reasons":["No PRISMA full-text exclusion-stage filter was applied."]}}